keyword
https://read.qxmd.com/read/38454771/a-phase-i-clinical-study-of-the-pharmacokinetics-and-safety-of-prusogliptin-tablets-in-subjects-with-mild-to-moderate-hepatic-insufficiency-and-normal-liver-function
#21
JOURNAL ARTICLE
Huiting Zhang, Yicong Bian, Weifeng Zhao, Liyan Miao, Hua Zhang, Juanjuan Cui, Xiaofang Zhang, Xueyuan Zhang, Wen Cai
BACKGROUND: Prusogliptin is a potent and selective DPP-4 inhibitor. In different animal models, Prusogliptin showed potential efficacy in the treatment of type 2 diabetes. However, the knowledge of its pharmacokinetics and safety in patients with liver dysfunction is limited. OBJECTIVES: The present study evaluated the pharmacokinetics and safety of Prusogliptin in subjects with mild or moderate hepatic impairment compared with healthy subjects. METHODS: According to the liver function of the subjects, we divided them into a mild liver dysfunction group, a moderate liver dysfunction group and a normal liver function group...
March 5, 2024: Current Drug Metabolism
https://read.qxmd.com/read/38422562/increased-skeletal-muscle-mass-index-was-involved-in-glycemic-efficacy-following-diabetes-treatment-and-changes-in-fat-mass-index-correlated-with-the-changes-in-the-lipid-ratio-in-type-2-diabetes
#22
JOURNAL ARTICLE
Shun Matsuura, Soichiro Nagata, Koji Shibazaki, Reiko Uchida, Yukiko Imai, Shoko Shibata, Hiroshi Morita
AIM: This study aimed to investigate the association between changes in body composition, glycated hemoglobin, and lipid ratio during the treatment of patients with type 2 diabetes mellitus (T2DM). METHODS: This retrospective analysis used data from outpatients with T2DM who had confirmed body composition and measured laboratories at administration and after treatment. The baseline characteristics and prescribed treatment were collected. The total cholesterol/high-density lipoprotein cholesterol (HDL) ratio, low-density lipoprotein cholesterol (LDL)/HDL ratio, and triglyceride-glucose (TyG) index were also calculated...
February 27, 2024: Journal of Diabetes and its Complications
https://read.qxmd.com/read/38406268/pre1brazil-protocol-a-randomized-controlled-trial-to-evaluate-the-effectiveness-and-safety-of-the-dpp-4-inhibitor-alogliptin-in-delaying-the-progression-of-stage-2-type-1-diabetes
#23
JOURNAL ARTICLE
Jaquellyne Gurgel Penaforte-Saboia, Carlos Eduardo Barra Couri, Natasha Vasconcelos Albuquerque, Lana Livia Peixoto Linard, Daniel Autran Cavalcante Araújo, Sherida Karanini Paz de Oliveira, Thisciane Ferreira Pinto Gomes, Marcelo Maia Pinheiro, Maria Helane Costa Gurgel Castelo, Virgínia Oliveira Fernandes, Renan Magalhães Montenegro Júnior
BACKGROUND: The incidence of Type 1 Diabetes Mellitus (T1DM) is on the rise. Since there is no curative treatment, it is urgent to look for therapies that can delay disease progression and protect pancreatic β-cells. Dipeptidyl peptidase-4 inhibitors (DPP-4i) have shown potential in modulating inflammation and preventing β-cell destruction. This protocol describes an upcoming trial to evaluate the effectiveness of the DPP-4i alogliptin in delaying the progression of stage 2 (presymptomatic) to stage 3 (symptomatic) T1DM...
2024: Diabetes, Metabolic Syndrome and Obesity
https://read.qxmd.com/read/38405679/expert-evaluation-of-efficacy-and-rationality-of-vildagliptin-ever-vilda-an-indian-perspective
#24
JOURNAL ARTICLE
Sanjay Kalra, Abdul Hamid Zargar, G R Sridhar, Ashok Kumar Das, Jamal Ahmed, Jagdish Chander Mohan, G Vijayakumar, Ajay Kumar, Rakesh Kumar Sahay, Vageesh Ayer, Kaushik Pandit, Ganapathi Bantwal, Arun Srinivas, A G Unnikrishnan, Sushil Jindal, Saumitra Ray, Manash P Baruah, Kajal Ganguly, Sachin Mittal, Ameya Joshi, Joe George, Ganesh Hk, Nitin Kapoor, Santosh Ramakrishnan, Chetan Shah, Atul Dhingra, Balram Sharma
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy. In India, Vildagliptin is commonly prescribed in T2DM patients because it reduces mean amplitude of glycemic excursion (MAGE), has lower risk of hypoglycemia and is weight neutral. Early combination therapy with vildagliptin and metformin is effective and well-tolerated in patients with T2DM, regardless of age or ethnicity...
2024: Clinical Medicine Insights. Endocrinology and Diabetes
https://read.qxmd.com/read/38405500/synthesis-structural-elucidation-in-silico-and-in-vitro-studies-of-new-class-of-methylenedioxyphenyl-based-amide-derivatives-as-potential-myeloperoxidase-inhibitors-for-cardiovascular-protection
#25
JOURNAL ARTICLE
Reshma Rajan, Sambantham Karthikeyan, Rajagopal Desikan
Novel methylenedioxyphenyl-based amides, especially N -(4-methoxybenzyl)-6-nitrobenzo-[1,3]-dioxole-5-carboxamide (MDC) and N -(3-acetylphenyl)-6-nitrobenzo-[1,3]-dioxole-5-carboxamide (ADC), potential cardiovascular preventive agents, are successfully synthesized, and their chemical structures are verified by 1 H and 13 C NMR, Fourier transform infrared (FT-IR), high-resolution mass spectrometry (HRMS), and single-crystal X-ray diffraction (SC-XRD) analyses. Data obtained from SC-XRD reveal that MDC and ADC are both monoclinic molecules with Z = 2 and 4, respectively...
February 20, 2024: ACS Omega
https://read.qxmd.com/read/38405148/management-of-pasireotide-induced-hyperglycemia-in-patients-with-acromegaly-an-experts-consensus-statement
#26
JOURNAL ARTICLE
Sylvère Störmann, Sebastian M Meyhöfer, Jan B Groener, Johanna Faust, Katharina Schilbach, Jochen Seufert, Bruno Vergès
Pasireotide is a somatostatin analogue for the treatment of acromegaly, a chronic condition caused by excess growth hormone. Despite the therapeutic benefits of pasireotide as a second-line treatment for inadequately controlled acromegaly, a major concern is its hyperglycemic side-effect. Here, we provide guidance on how to select appropriate patients with acromegaly for treatment with pasireotide. We summarize baseline characteristics of patients at high risk for pasireotide-associated hyperglycemia and recommend a monitoring strategy based on the risk profile...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38402457/comparison-between-sodium-glucose-cotransporter-2-inhibitors-and-dipeptidyl-peptidase-4-inhibitors-on-the-risk-of-incident-cancer-in-patients-with-diabetes-mellitus-a-real-world-evidence-study
#27
COMPARATIVE STUDY
Hui-Lin Sung, Chuan-Yu Hung, Yu-Chun Tung, Chih-Chung Lin, Tung-Han Tsai, Kuang-Hua Huang
AIMS: Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) have been demonstrated to be associated with cancer cell mechanisms. However, whether they increase the risk of cancer remains unclear. Thus, this study aimed to determine the association between SGLT-2i use and the incidence of cancer in patients with diabetes mellitus (DM) in Taiwan. MATERIALS AND METHODS: This retrospective cohort study was based on the Taiwan National Health Insurance database. The study population comprised patients with DM, and those who first used SGLT-2is during 2016-2018 were assigned to the study group...
March 2024: Diabetes/metabolism Research and Reviews
https://read.qxmd.com/read/38396657/risks-and-benefits-of-sglt-2-inhibitors-for-type-1-diabetes-patients-using-automated-insulin-delivery-systems-a-literature-review
#28
REVIEW
Viviana Elian, Violeta Popovici, Oana Karampelas, Gratiela Gradisteanu Pircalabioru, Gabriela Radulian, Madalina Musat
The primary treatment for autoimmune Diabetes Mellitus (Type 1 Diabetes Mellitus-T1DM) is insulin therapy. Unfortunately, a multitude of clinical cases has demonstrated that the use of insulin as a sole therapeutic intervention fails to address all issues comprehensively. Therefore, non-insulin adjunct treatment has been investigated and shown successful results in clinical trials. Various hypoglycemia-inducing drugs such as Metformin, glucagon-like peptide 1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, amylin analogs, and Sodium-Glucose Cotransporters 2 (SGLT-2) inhibitors, developed good outcomes in patients with T1DM...
February 6, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38390500/stereochemical-insights-into-%C3%AE-amino-n-acylhydrazones-and-their-impact-on-dpp-4-inhibition
#29
JOURNAL ARTICLE
Eduardo Reina, Lucas Silva Franco, Teiliane Rodrigues Carneiro, Eliezer J Barreiro, Lidia Moreira Lima
Dipeptidyl peptidase IV (DPP-4) is a key enzyme that regulates several important biological processes and it is better known to be targeted by gliptins as a modern validated approach for the management of type 2 diabetes mellitus (T2DM). However, new generations of DPP-4 inhibitors capable of controlling inflammatory processes associated with chronic complications of T2DM are still needed. In this scenario, we report here the design by molecular modelling of new β-amino- N -acylhydrazones, their racemic synthesis, chiral resolution, determination of physicochemical properties and their DPP4 inhibitory potency...
February 21, 2024: RSC Advances
https://read.qxmd.com/read/38384297/emerging-role-of-antidiabetic-drugs-in-cardiorenal-protection
#30
REVIEW
Wen-Jia Fu, Jin-Ling Huo, Zi-Hui Mao, Shao-Kang Pan, Dong-Wei Liu, Zhang-Suo Liu, Peng Wu, Zhong-Xiuzi Gao
The global prevalence of diabetes mellitus (DM) has led to widespread multi-system damage, especially in cardiovascular and renal functions, heightening morbidity and mortality. Emerging antidiabetic drugs sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4i) have demonstrated efficacy in preserving cardiac and renal function, both in type 2 diabetic and non-diabetic individuals. To understand the exact impact of these drugs on cardiorenal protection and underlying mechanisms, we conducted a comprehensive review of recent large-scale clinical trials and basic research focusing on SGLT2i, GLP-1RAs, and DPP-4i...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38379094/glycaemic-control-and-macrovascular-and-microvascular-outcomes-in-type-2-diabetes-systematic-review-and-meta-analysis-of-cardiovascular-outcome-trials-of-novel-glucose-lowering-agents
#31
JOURNAL ARTICLE
Setor K Kunutsor, Francesco Zaccardi, Victoria G Balasubramanian, Clare L Gillies, Vanita R Aroda, Samuel Seidu, Melanie J Davies, Kamlesh Khunti
AIM: Using a systematic review and meta-analysis of placebo-controlled cardiovascular outcome trials (CVOTs) of newer glucose-lowering agents [sodium-glucose cotransporter-2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4is)] in type 2 diabetes (T2D), we aimed to determine the macrovascular and microvascular outcomes of these agents and clarify the relationships between glycated haemoglobin (HbA1c) reduction and risk of these outcomes...
February 20, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38369592/effectiveness-of-oral-semaglutide-on-glucose-control-and-body-weight-up-to-18-months-a-multicenter-retrospective-real-world-study
#32
JOURNAL ARTICLE
B M Bonora, G Russo, F Leonetti, M Strazzabosco, L Nollino, G Aimaretti, A Giaccari, F Broglio, A Consoli, A Avogaro, G P Fadini
AIM: Oral semaglutide, an innovative orally administered GLP-1 receptor agonist for type 2 diabetes (T2D) management was herein evaluated for its effectiveness in a multi-center retrospective real-world study. METHODS: We included new-users of oral semaglutide from 18 specialist care centres and collected retrospective data on baseline clinical characteristics. Updated values of HbA1c and body weight were analyzed using the mixed model for repeated measures. RESULTS: The study included 166 individuals with T2D, predominantly men (64...
February 18, 2024: Journal of Endocrinological Investigation
https://read.qxmd.com/read/38367467/a-novel-mechanism-of-vildagliptin-in-regulating-bone-metabolism-and-mitigating-osteoporosis
#33
JOURNAL ARTICLE
Jinwen He, Dacheng Zhao, Bo Peng, Xingwen Wang, Shenghong Wang, Xiaobing Zhao, Peng Xu, Bin Geng, Yayi Xia
Osteoporosis has become a global social problem with the tendency toward the aging population. The challenge in managing osteoporosis is to develop new anti-osteoporosis drugs that target bone anabolism. The purpose of this study was to uncover the novel mechanism of Vildagliptin on bone metabolism. We revealed that Vildagliptin significantly promoted osteogenic differentiation of precursor osteoblasts and bone marrow mesenchymal stem cells (BMSCs). At the same time, it significantly enhanced the polarization of RAW264...
February 16, 2024: International Immunopharmacology
https://read.qxmd.com/read/38367257/time-dependent-risk-of-fracture-in-adults-with-type-2-diabetes-receiving-anti-diabetic-drug-a-one-stage-network-meta-analysis
#34
JOURNAL ARTICLE
Yanjiao Shen, Qingyang Shi, Xinyu Zou, Wentong Meng, Haoming Tian, Liang Du, Sheyu Li
AIMS: To assess the time-dependent risk of fracture in adults with type 2 diabetes receiving anti-diabetic drugs. MATERIALS AND METHODS: We searched MEDLINE, EMBASE, and Cochrane Library up to 18 November 2021, for randomized controlled trials (RCTs) and propensity-score-matched non-randomized studies (NRSs) comparing all anti-diabetic drugs with standard treatment or with each other on fracture in adults with type 2 diabetes. The study performed a one-stage network meta-analysis using discrete-time hazard regression with reconstructed individual time-to-event data...
February 2024: Diabetes/metabolism Research and Reviews
https://read.qxmd.com/read/38354025/linagliptin-a-dpp-4-inhibitor-activates-ampk-foxo3a-and-suppresses-nf%C3%AE%C2%BAb-to-mitigate-the-debilitating-effects-of-diethylnitrosamine-exposure-in-rat-liver-novel-mechanistic-insights
#35
JOURNAL ARTICLE
Rasha Abdelhady, Osama A Mohammed, Ahmed S Doghish, Rabab S Hamad, Mustafa Ahmed Abdel-Reheim, Mohannad Mohammad S Alamri, Muffarah Hamid Alharthi, Jaber Alfaifi, Masoud I E Adam, Abdullah Hassan Alhalafi, Nahid A Mohammed, Adamu Imam Isa, Sameh Abdel-Ghany, Mohammed A Attia, Elsayed A Elmorsy, Tohada M Al-Noshokaty, Yousra Nomier, Walaa A El-Dakroury, Sameh Saber
Accumulating evidence suggests that dysregulation of FOXO3a plays a significant role in the progression of various malignancies, including hepatocellular carcinoma (HCC). FOXO3a inactivation, driven by oncogenic stimuli, can lead to abnormal cell growth, suppression of apoptosis, and resistance to anticancer drugs. Therefore, FOXO3a emerges as a potential molecular target for the development of innovative treatments in the era of oncology. Linagliptin (LNGTN), a DPP-4 inhibitor known for its safe profile, has exhibited noteworthy anti-inflammatory and anti-oxidative properties in previous in vivo studies...
February 29, 2024: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://read.qxmd.com/read/38345802/outcomes-of-various-classes-of-oral-antidiabetic-drugs-on-nonalcoholic-fatty-liver-disease
#36
JOURNAL ARTICLE
Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Soo Lim, Woojoo Lee, Won Kim
IMPORTANCE: Several oral antidiabetic drug (OAD) classes can potentially improve patient outcomes in nonalcoholic fatty liver disease (NAFLD) to varying degrees, but clinical data on which class is favored are lacking. OBJECTIVE: To investigate which OAD is associated with the best patient outcomes in NAFLD and type 2 diabetes (T2D). DESIGN, SETTING, AND PARTICIPANTS: This retrospective nonrandomized interventional cohort study used the National Health Information Database, which provided population-level data for Korea...
February 12, 2024: JAMA Internal Medicine
https://read.qxmd.com/read/38337597/dipeptidyl-peptidase-4-and-glucagon-like-peptide-1-a-link-in-the-connection-between-periodontitis-and-diabetes-mellitus-what-do-we-know-so-far-a-scoping-review
#37
REVIEW
Theodora Claudia Gheonea, Petra Șurlin, Flavia Mirela Nicolae, Dorin Nicolae Gheorghe, Dora Maria Popescu, Ion Rogoveanu
Periodontitis is a common condition affecting the tissues surrounding and supporting teeth. In addition to oral health concerns, periodontal disease increases the chance of developing systemic illnesses including type 2 diabetes mellitus. Porphyromonas gingivalis, a key-stone pathogen that has been linked to the pathophysiology of periodontal disease, can generate a series of dipeptide producing exopeptidases, dipeptidyl peptidases (DPP). DPP-4 levels in gingival crevicular fluid have been shown to increase during active periodontal disease, which may lead to their association with the disease's progression...
February 4, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38328413/long-term-benefits-of-dapagliflozin-on-renal-outcomes-of-type-2-diabetes-under-routine-care-a-comparative-effectiveness-study-on-propensity-score-matched-cohorts-at-low-renal-risk
#38
JOURNAL ARTICLE
Gian Paolo Fadini, Enrico Longato, Mario Luca Morieri, Stefano Del Prato, Angelo Avogaro, Anna Solini
BACKGROUND: Despite the overall improvement in care, people with type 2 diabetes (T2D) experience an excess risk of end-stage kidney disease. We evaluated the long-term effectiveness of dapagliflozin on kidney function and albuminuria in patients with T2D. METHODS: We included patients with T2D who initiated dapagliflozin or comparators from 2015 to 2020. Propensity score matching (PSM) was performed to balance the two groups. The primary endpoint was the change in estimated glomerular filtration rate (eGFR) from baseline to the end of observation...
March 2024: The Lancet regional health. Europe
https://read.qxmd.com/read/38326167/proteomic-changes-related-to-actin-cytoskeleton-function-in-the-skin-of-vildagliptin-treated-mice
#39
JOURNAL ARTICLE
Antti Nätynki, Nina Kokkonen, Jussi Tuusa, Steffen Ohlmeier, Ulrich Bergmann, Kaisa Tasanen
BACKGROUND: Vildagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i) is a widely used type 2 diabetes medication that is associated with an up-to 10-fold increased risk for the development of bullous pemphigoid (BP), an autoimmune skin disease. The mechanism by which vildagliptin promotes the development of BP remains unknown. OBJECTIVE: To elucidate effects of vildagliptin treatment on the mouse cutaneous proteome. METHODS: We analyzed the cutaneous proteome of nondiabetic mice treated for 12 weeks with vildagliptin using label-free shotgun mass spectrometry (MS), two-dimensional difference gel electrophoresis (2D-DIGE), immunohistochemistry, immunoblotting, and quantitative real-time polymerase chain reaction...
January 20, 2024: Journal of Dermatological Science
https://read.qxmd.com/read/38323861/effects-of-dipeptidyl-peptidase-4-inhibition-in%C3%A2-vivo-dipeptidyl-peptidase-4-inhibitor-gut-microbiome-crosstalk-suggests-novel-therapeutic-options-for-diabetes-management
#40
JOURNAL ARTICLE
Takuma Yasuda, Norio Harada, Nobuya Inagaki
Wang et al. report that clinical dipeptidyl peptidase-4 (DPP-4) inhibitors show little effect on microbial DPP-4 produced by Bacteroides genus. Furthermore, oral administration of microbial DPP-4 to high-fat diet-fed mice was found to reduce plasma active glucagon-like peptide-1 levels through an increase in extraluminal intestinal tissular DPP-4 activity, resulting in reduced glucose-induced insulin levels and exacerbated glucose tolerance.
February 7, 2024: Journal of Diabetes Investigation
keyword
keyword
69346
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.